High‐content drug screening for rare diseases

Abstract

Per definition, rare diseases affect only a small number of subjects within a given population. Taken together however, they represent a considerable medical burden, which remains poorly addressed in terms of treatment. Compared to other diseases, obstacles to the development of therapies for rare diseases include less extensive physiopathology knowledge, limited number of patients to test treatments, and poor commercial interest from the industry. Recently, advances in high-throughput and high-content screening (HTS and HCS) have been fostered by the development of specific routines that use robot- and computer-assisted technologies to automatize tasks, allowing screening of a large number of compounds in a short period of time, using experimental model of diseases. These approaches are particularly relevant for drug repositioning in rare disease, which restricts the search to compounds that have already been tested in humans, thereby reducing the need for extensive preclinical tests. In the future, these same tools, combined with computational modeling and artificial neural network analyses, may also be used to predict individual clinical responses to drugs in a personalized medicine approach.

Mitochondrial Dynamics of Proximal Tubular Epithelial Cells in Nephropathic Cystinosis

“…MEA treatment restored mitochondrial size, cristae number, and lumen, but had no effect on cristae junction width, making tubular cells more susceptible to apoptotic stimuli. In this contest, we highlight several cellular mediators of mitochondrial dynamics that could be useful to develop new therapeutic interventions [41].…”

Orthogonal linear separation analysis: an approach to decompose the complex effects of a perturbagen

“…Drug discovery with drug repositioning has been a successful approach (Tan et al, 2018;Mercorelli et al, 2018;Panchapakesan & Pollock, 2018). The approach mostly depends on serendipity in the beginning, but the various methodologies based on scientific evidence such as screening systems and in silico prediction of drug-molecule interaction have been established, which contribute to the development of the approach (Bellomo et al, 2017;Datta et al, 2018;Karaman B, 2018). The success of drug repositioning implies that the effect of a drug is complex and composed of multiple more basic components.…”

PurifyR: An R Package for Highly Automated, Reproducible Variable Extraction and Standardization

“…When these steps are not documented, the results can be nearly impossible to reproduce and can lead to experimental results that cannot be reused or compared with subsequent projects and findings. 19 Many packages currently exist for preprocessing datasets 20 to meet the assumptions of statistical testing methods and machine learning models. However, few methods exist that can comprehensively automate the majority of preprocessing steps in both documentation and reproducibility in a manner sufficient to meet the necessary fundamental assumptions conceivable for most statistical methods such as outlier handling, missing data imputation, and feature selection.…”